nodes	percent_of_prediction	percent_of_DWPC	metapath
Dalfampridine—KCNH7—Circadian rythm related genes—ID4—osteoporosis	0.00506	0.022	CbGpPWpGaD
Dalfampridine—KCNG2—Regulation of insulin secretion—RAP1A—osteoporosis	0.00407	0.0177	CbGpPWpGaD
Dalfampridine—KCNS3—Regulation of insulin secretion—RAP1A—osteoporosis	0.00407	0.0177	CbGpPWpGaD
Dalfampridine—KCNC2—Regulation of insulin secretion—RAP1A—osteoporosis	0.00407	0.0177	CbGpPWpGaD
Dalfampridine—KCNB1—Regulation of insulin secretion—RAP1A—osteoporosis	0.00386	0.0168	CbGpPWpGaD
Dalfampridine—KCNC2—Glucagon-like Peptide-1 (GLP1) regulates insulin secretion—ADCY5—osteoporosis	0.00349	0.0152	CbGpPWpGaD
Dalfampridine—KCNG2—Glucagon-like Peptide-1 (GLP1) regulates insulin secretion—ADCY5—osteoporosis	0.00349	0.0152	CbGpPWpGaD
Dalfampridine—KCNS3—Glucagon-like Peptide-1 (GLP1) regulates insulin secretion—ADCY5—osteoporosis	0.00349	0.0152	CbGpPWpGaD
Dalfampridine—KCNB1—Glucagon-like Peptide-1 (GLP1) regulates insulin secretion—ADCY5—osteoporosis	0.00331	0.0144	CbGpPWpGaD
Dalfampridine—KCNG2—Integration of energy metabolism—RAP1A—osteoporosis	0.0032	0.0139	CbGpPWpGaD
Dalfampridine—KCNS3—Integration of energy metabolism—RAP1A—osteoporosis	0.0032	0.0139	CbGpPWpGaD
Dalfampridine—KCNC2—Integration of energy metabolism—RAP1A—osteoporosis	0.0032	0.0139	CbGpPWpGaD
Dalfampridine—KCNA3—BDNF signaling pathway—RAP1A—osteoporosis	0.00308	0.0134	CbGpPWpGaD
Dalfampridine—KCNB1—Integration of energy metabolism—RAP1A—osteoporosis	0.00303	0.0132	CbGpPWpGaD
Dalfampridine—KCNA3—BDNF signaling pathway—ALPL—osteoporosis	0.00296	0.0129	CbGpPWpGaD
Dalfampridine—Anxiety—Calcitriol—osteoporosis	0.00274	0.00356	CcSEcCtD
Dalfampridine—Mental disorder—Risedronate—osteoporosis	0.00274	0.00356	CcSEcCtD
Dalfampridine—Skin disorder—Estropipate—osteoporosis	0.00273	0.00355	CcSEcCtD
Dalfampridine—Infection—Raloxifene—osteoporosis	0.00271	0.00351	CcSEcCtD
Dalfampridine—Nasopharyngitis—Estradiol—osteoporosis	0.00271	0.00351	CcSEcCtD
Dalfampridine—Back pain—Ethinyl Estradiol—osteoporosis	0.0027	0.00351	CcSEcCtD
Dalfampridine—Angiopathy—Pamidronate—osteoporosis	0.0027	0.0035	CcSEcCtD
Dalfampridine—Anaphylactic shock—Ibandronate—osteoporosis	0.0027	0.0035	CcSEcCtD
Dalfampridine—Immune system disorder—Pamidronate—osteoporosis	0.00269	0.00349	CcSEcCtD
Dalfampridine—Mediastinal disorder—Pamidronate—osteoporosis	0.00268	0.00348	CcSEcCtD
Dalfampridine—Infection—Ibandronate—osteoporosis	0.00268	0.00348	CcSEcCtD
Dalfampridine—Feeling abnormal—Etidronic acid—osteoporosis	0.00268	0.00348	CcSEcCtD
Dalfampridine—Nervous system disorder—Raloxifene—osteoporosis	0.00267	0.00347	CcSEcCtD
Dalfampridine—Connective tissue disorder—Zoledronate—osteoporosis	0.00267	0.00347	CcSEcCtD
Dalfampridine—Skin disorder—Raloxifene—osteoporosis	0.00265	0.00344	CcSEcCtD
Dalfampridine—Nervous system disorder—Ibandronate—osteoporosis	0.00264	0.00343	CcSEcCtD
Dalfampridine—Anaphylactic shock—Calcitriol—osteoporosis	0.00264	0.00343	CcSEcCtD
Dalfampridine—Back pain—Risedronate—osteoporosis	0.00263	0.00342	CcSEcCtD
Dalfampridine—Skin disorder—Ibandronate—osteoporosis	0.00262	0.0034	CcSEcCtD
Dalfampridine—KCNA3—BDNF signaling pathway—BMP2—osteoporosis	0.0026	0.0113	CbGpPWpGaD
Dalfampridine—Nausea—Ergocalciferol—osteoporosis	0.0026	0.00337	CcSEcCtD
Dalfampridine—Urticaria—Etidronic acid—osteoporosis	0.00258	0.00335	CcSEcCtD
Dalfampridine—Skin disorder—Calcitriol—osteoporosis	0.00256	0.00333	CcSEcCtD
Dalfampridine—Angioedema—Ethinyl Estradiol—osteoporosis	0.00255	0.00331	CcSEcCtD
Dalfampridine—Insomnia—Estropipate—osteoporosis	0.00254	0.0033	CcSEcCtD
Dalfampridine—Paraesthesia—Estropipate—osteoporosis	0.00252	0.00328	CcSEcCtD
Dalfampridine—Back pain—Pamidronate—osteoporosis	0.0025	0.00325	CcSEcCtD
Dalfampridine—Angioedema—Risedronate—osteoporosis	0.00249	0.00323	CcSEcCtD
Dalfampridine—Dyspepsia—Estropipate—osteoporosis	0.00248	0.00321	CcSEcCtD
Dalfampridine—Angiopathy—Zoledronate—osteoporosis	0.00246	0.0032	CcSEcCtD
Dalfampridine—Insomnia—Raloxifene—osteoporosis	0.00246	0.0032	CcSEcCtD
Dalfampridine—Immune system disorder—Zoledronate—osteoporosis	0.00245	0.00319	CcSEcCtD
Dalfampridine—Mediastinal disorder—Zoledronate—osteoporosis	0.00245	0.00318	CcSEcCtD
Dalfampridine—Insomnia—Ibandronate—osteoporosis	0.00244	0.00317	CcSEcCtD
Dalfampridine—Dyspepsia—Alendronate—osteoporosis	0.00244	0.00317	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Estropipate—osteoporosis	0.00243	0.00315	CcSEcCtD
Dalfampridine—Paraesthesia—Ibandronate—osteoporosis	0.00242	0.00314	CcSEcCtD
Dalfampridine—Constipation—Estropipate—osteoporosis	0.0024	0.00312	CcSEcCtD
Dalfampridine—Dyspepsia—Raloxifene—osteoporosis	0.0024	0.00311	CcSEcCtD
Dalfampridine—Hypersensitivity—Etidronic acid—osteoporosis	0.00239	0.00311	CcSEcCtD
Dalfampridine—Insomnia—Calcitriol—osteoporosis	0.00239	0.0031	CcSEcCtD
Dalfampridine—Mental disorder—Zoledronate—osteoporosis	0.00238	0.00309	CcSEcCtD
Dalfampridine—Dyspepsia—Ibandronate—osteoporosis	0.00237	0.00308	CcSEcCtD
Dalfampridine—Angiopathy—Conjugated Estrogens—osteoporosis	0.00237	0.00308	CcSEcCtD
Dalfampridine—Anxiety—Ethinyl Estradiol—osteoporosis	0.00237	0.00308	CcSEcCtD
Dalfampridine—Constipation—Alendronate—osteoporosis	0.00237	0.00308	CcSEcCtD
Dalfampridine—Angioedema—Pamidronate—osteoporosis	0.00237	0.00307	CcSEcCtD
Dalfampridine—Immune system disorder—Conjugated Estrogens—osteoporosis	0.00236	0.00307	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.00236	0.00307	CcSEcCtD
Dalfampridine—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.00236	0.00306	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Raloxifene—osteoporosis	0.00235	0.00305	CcSEcCtD
Dalfampridine—Infestation—Estradiol—osteoporosis	0.00233	0.00303	CcSEcCtD
Dalfampridine—Infestation NOS—Estradiol—osteoporosis	0.00233	0.00303	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Ibandronate—osteoporosis	0.00233	0.00302	CcSEcCtD
Dalfampridine—Chest pain—Risedronate—osteoporosis	0.00232	0.00301	CcSEcCtD
Dalfampridine—Anxiety—Risedronate—osteoporosis	0.00231	0.003	CcSEcCtD
Dalfampridine—Constipation—Ibandronate—osteoporosis	0.00231	0.00299	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.0023	0.00299	CcSEcCtD
Dalfampridine—Mental disorder—Conjugated Estrogens—osteoporosis	0.00229	0.00298	CcSEcCtD
Dalfampridine—Back pain—Zoledronate—osteoporosis	0.00229	0.00297	CcSEcCtD
Dalfampridine—Feeling abnormal—Alendronate—osteoporosis	0.00228	0.00296	CcSEcCtD
Dalfampridine—Urinary tract infection—Estradiol—osteoporosis	0.00227	0.00294	CcSEcCtD
Dalfampridine—Infection—Ethinyl Estradiol—osteoporosis	0.00226	0.00294	CcSEcCtD
Dalfampridine—Constipation—Calcitriol—osteoporosis	0.00226	0.00293	CcSEcCtD
Dalfampridine—Convulsion—Pamidronate—osteoporosis	0.00224	0.00291	CcSEcCtD
Dalfampridine—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.00224	0.0029	CcSEcCtD
Dalfampridine—Urticaria—Estropipate—osteoporosis	0.00223	0.0029	CcSEcCtD
Dalfampridine—Feeling abnormal—Ibandronate—osteoporosis	0.00222	0.00289	CcSEcCtD
Dalfampridine—Tremor—Zoledronate—osteoporosis	0.00222	0.00288	CcSEcCtD
Dalfampridine—Skin disorder—Ethinyl Estradiol—osteoporosis	0.00221	0.00288	CcSEcCtD
Dalfampridine—Infection—Risedronate—osteoporosis	0.00221	0.00287	CcSEcCtD
Dalfampridine—Back pain—Conjugated Estrogens—osteoporosis	0.0022	0.00286	CcSEcCtD
Dalfampridine—Urticaria—Alendronate—osteoporosis	0.0022	0.00286	CcSEcCtD
Dalfampridine—Anxiety—Pamidronate—osteoporosis	0.0022	0.00285	CcSEcCtD
Dalfampridine—Nervous system disorder—Risedronate—osteoporosis	0.00218	0.00283	CcSEcCtD
Dalfampridine—Angioedema—Zoledronate—osteoporosis	0.00216	0.00281	CcSEcCtD
Dalfampridine—Skin disorder—Risedronate—osteoporosis	0.00216	0.0028	CcSEcCtD
Dalfampridine—KCNG2—Regulation of insulin secretion—ADCY5—osteoporosis	0.00215	0.00934	CbGpPWpGaD
Dalfampridine—KCNC2—Regulation of insulin secretion—ADCY5—osteoporosis	0.00215	0.00934	CbGpPWpGaD
Dalfampridine—KCNS3—Regulation of insulin secretion—ADCY5—osteoporosis	0.00215	0.00934	CbGpPWpGaD
Dalfampridine—Urticaria—Ibandronate—osteoporosis	0.00214	0.00278	CcSEcCtD
Dalfampridine—Confusional state—Pamidronate—osteoporosis	0.00213	0.00277	CcSEcCtD
Dalfampridine—Anaphylactic shock—Pamidronate—osteoporosis	0.00211	0.00274	CcSEcCtD
Dalfampridine—Infection—Pamidronate—osteoporosis	0.0021	0.00273	CcSEcCtD
Dalfampridine—Urticaria—Calcitriol—osteoporosis	0.0021	0.00272	CcSEcCtD
Dalfampridine—Angioedema—Conjugated Estrogens—osteoporosis	0.00208	0.0027	CcSEcCtD
Dalfampridine—Hypersensitivity—Estropipate—osteoporosis	0.00207	0.00269	CcSEcCtD
Dalfampridine—Nervous system disorder—Pamidronate—osteoporosis	0.00207	0.00269	CcSEcCtD
Dalfampridine—Vomiting—Etidronic acid—osteoporosis	0.00207	0.00268	CcSEcCtD
Dalfampridine—KCNQ1—SIDS Susceptibility Pathways—GAPDH—osteoporosis	0.00206	0.00895	CbGpPWpGaD
Dalfampridine—Connective tissue disorder—Estradiol—osteoporosis	0.00206	0.00267	CcSEcCtD
Dalfampridine—Rash—Etidronic acid—osteoporosis	0.00205	0.00266	CcSEcCtD
Dalfampridine—Convulsion—Zoledronate—osteoporosis	0.00205	0.00266	CcSEcCtD
Dalfampridine—Dermatitis—Etidronic acid—osteoporosis	0.00205	0.00266	CcSEcCtD
Dalfampridine—Hypersensitivity—Alendronate—osteoporosis	0.00204	0.00265	CcSEcCtD
Dalfampridine—KCNB1—Regulation of insulin secretion—ADCY5—osteoporosis	0.00204	0.00885	CbGpPWpGaD
Dalfampridine—Headache—Etidronic acid—osteoporosis	0.00204	0.00264	CcSEcCtD
Dalfampridine—Asthenia—Estropipate—osteoporosis	0.00202	0.00262	CcSEcCtD
Dalfampridine—Chest pain—Zoledronate—osteoporosis	0.00201	0.00261	CcSEcCtD
Dalfampridine—Insomnia—Risedronate—osteoporosis	0.00201	0.00261	CcSEcCtD
Dalfampridine—Anxiety—Zoledronate—osteoporosis	0.00201	0.00261	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.002	0.0026	CcSEcCtD
Dalfampridine—Paraesthesia—Risedronate—osteoporosis	0.002	0.00259	CcSEcCtD
Dalfampridine—Asthenia—Alendronate—osteoporosis	0.00199	0.00258	CcSEcCtD
Dalfampridine—Hypersensitivity—Ibandronate—osteoporosis	0.00199	0.00258	CcSEcCtD
Dalfampridine—Dyspnoea—Risedronate—osteoporosis	0.00198	0.00257	CcSEcCtD
Dalfampridine—Hypotension—Pamidronate—osteoporosis	0.00197	0.00256	CcSEcCtD
Dalfampridine—Convulsion—Conjugated Estrogens—osteoporosis	0.00197	0.00256	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.00197	0.00256	CcSEcCtD
Dalfampridine—Dyspepsia—Risedronate—osteoporosis	0.00196	0.00254	CcSEcCtD
Dalfampridine—Constipation—Ethinyl Estradiol—osteoporosis	0.00195	0.00253	CcSEcCtD
Dalfampridine—Confusional state—Zoledronate—osteoporosis	0.00195	0.00253	CcSEcCtD
Dalfampridine—Hypersensitivity—Calcitriol—osteoporosis	0.00194	0.00253	CcSEcCtD
Dalfampridine—Chest pain—Conjugated Estrogens—osteoporosis	0.00194	0.00252	CcSEcCtD
Dalfampridine—Asthenia—Ibandronate—osteoporosis	0.00193	0.00251	CcSEcCtD
Dalfampridine—Anxiety—Conjugated Estrogens—osteoporosis	0.00193	0.00251	CcSEcCtD
Dalfampridine—Nausea—Etidronic acid—osteoporosis	0.00193	0.00251	CcSEcCtD
Dalfampridine—Anaphylactic shock—Zoledronate—osteoporosis	0.00193	0.00251	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.00192	0.0025	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Risedronate—osteoporosis	0.00192	0.00249	CcSEcCtD
Dalfampridine—Infection—Zoledronate—osteoporosis	0.00192	0.00249	CcSEcCtD
Dalfampridine—Insomnia—Pamidronate—osteoporosis	0.00191	0.00248	CcSEcCtD
Dalfampridine—Constipation—Risedronate—osteoporosis	0.0019	0.00247	CcSEcCtD
Dalfampridine—Angiopathy—Estradiol—osteoporosis	0.0019	0.00247	CcSEcCtD
Dalfampridine—Paraesthesia—Pamidronate—osteoporosis	0.0019	0.00246	CcSEcCtD
Dalfampridine—Asthenia—Calcitriol—osteoporosis	0.00189	0.00246	CcSEcCtD
Dalfampridine—Nervous system disorder—Zoledronate—osteoporosis	0.00189	0.00246	CcSEcCtD
Dalfampridine—Immune system disorder—Estradiol—osteoporosis	0.00189	0.00246	CcSEcCtD
Dalfampridine—Mediastinal disorder—Estradiol—osteoporosis	0.00189	0.00245	CcSEcCtD
Dalfampridine—Dyspnoea—Pamidronate—osteoporosis	0.00188	0.00245	CcSEcCtD
Dalfampridine—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.00188	0.00244	CcSEcCtD
Dalfampridine—Skin disorder—Zoledronate—osteoporosis	0.00187	0.00243	CcSEcCtD
Dalfampridine—Dyspepsia—Pamidronate—osteoporosis	0.00186	0.00242	CcSEcCtD
Dalfampridine—Dizziness—Estropipate—osteoporosis	0.00186	0.00241	CcSEcCtD
Dalfampridine—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.00186	0.00241	CcSEcCtD
Dalfampridine—Infection—Conjugated Estrogens—osteoporosis	0.00185	0.0024	CcSEcCtD
Dalfampridine—Mental disorder—Estradiol—osteoporosis	0.00183	0.00238	CcSEcCtD
Dalfampridine—Dizziness—Alendronate—osteoporosis	0.00183	0.00238	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Pamidronate—osteoporosis	0.00182	0.00237	CcSEcCtD
Dalfampridine—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.00182	0.00237	CcSEcCtD
Dalfampridine—Urticaria—Ethinyl Estradiol—osteoporosis	0.00181	0.00235	CcSEcCtD
Dalfampridine—Constipation—Pamidronate—osteoporosis	0.00181	0.00235	CcSEcCtD
Dalfampridine—Skin disorder—Conjugated Estrogens—osteoporosis	0.0018	0.00234	CcSEcCtD
Dalfampridine—Hypotension—Zoledronate—osteoporosis	0.0018	0.00234	CcSEcCtD
Dalfampridine—Dizziness—Raloxifene—osteoporosis	0.0018	0.00234	CcSEcCtD
Dalfampridine—Vomiting—Estropipate—osteoporosis	0.00179	0.00232	CcSEcCtD
Dalfampridine—Dizziness—Ibandronate—osteoporosis	0.00178	0.00232	CcSEcCtD
Dalfampridine—Rash—Estropipate—osteoporosis	0.00177	0.0023	CcSEcCtD
Dalfampridine—Dermatitis—Estropipate—osteoporosis	0.00177	0.0023	CcSEcCtD
Dalfampridine—Urticaria—Risedronate—osteoporosis	0.00177	0.00229	CcSEcCtD
Dalfampridine—Back pain—Estradiol—osteoporosis	0.00176	0.00229	CcSEcCtD
Dalfampridine—Headache—Estropipate—osteoporosis	0.00176	0.00229	CcSEcCtD
Dalfampridine—Vomiting—Alendronate—osteoporosis	0.00176	0.00229	CcSEcCtD
Dalfampridine—Rash—Alendronate—osteoporosis	0.00175	0.00227	CcSEcCtD
Dalfampridine—Insomnia—Zoledronate—osteoporosis	0.00175	0.00227	CcSEcCtD
Dalfampridine—Dermatitis—Alendronate—osteoporosis	0.00174	0.00227	CcSEcCtD
Dalfampridine—Feeling abnormal—Pamidronate—osteoporosis	0.00174	0.00226	CcSEcCtD
Dalfampridine—Hypotension—Conjugated Estrogens—osteoporosis	0.00174	0.00225	CcSEcCtD
Dalfampridine—Headache—Alendronate—osteoporosis	0.00174	0.00225	CcSEcCtD
Dalfampridine—Paraesthesia—Zoledronate—osteoporosis	0.00173	0.00225	CcSEcCtD
Dalfampridine—Vomiting—Raloxifene—osteoporosis	0.00173	0.00225	CcSEcCtD
Dalfampridine—Dyspnoea—Zoledronate—osteoporosis	0.00172	0.00223	CcSEcCtD
Dalfampridine—Rash—Raloxifene—osteoporosis	0.00172	0.00223	CcSEcCtD
Dalfampridine—Dermatitis—Raloxifene—osteoporosis	0.00172	0.00223	CcSEcCtD
Dalfampridine—Vomiting—Ibandronate—osteoporosis	0.00171	0.00223	CcSEcCtD
Dalfampridine—Tremor—Estradiol—osteoporosis	0.00171	0.00222	CcSEcCtD
Dalfampridine—Headache—Raloxifene—osteoporosis	0.00171	0.00222	CcSEcCtD
Dalfampridine—Rash—Ibandronate—osteoporosis	0.0017	0.00221	CcSEcCtD
Dalfampridine—Dermatitis—Ibandronate—osteoporosis	0.0017	0.00221	CcSEcCtD
Dalfampridine—Dyspepsia—Zoledronate—osteoporosis	0.0017	0.00221	CcSEcCtD
Dalfampridine—KCNG2—Integration of energy metabolism—ADCY5—osteoporosis	0.00169	0.00734	CbGpPWpGaD
Dalfampridine—KCNC2—Integration of energy metabolism—ADCY5—osteoporosis	0.00169	0.00734	CbGpPWpGaD
Dalfampridine—KCNS3—Integration of energy metabolism—ADCY5—osteoporosis	0.00169	0.00734	CbGpPWpGaD
Dalfampridine—Headache—Ibandronate—osteoporosis	0.00169	0.00219	CcSEcCtD
Dalfampridine—Insomnia—Conjugated Estrogens—osteoporosis	0.00168	0.00218	CcSEcCtD
Dalfampridine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.00168	0.00218	CcSEcCtD
Dalfampridine—Vomiting—Calcitriol—osteoporosis	0.00168	0.00218	CcSEcCtD
Dalfampridine—Nausea—Estropipate—osteoporosis	0.00167	0.00217	CcSEcCtD
Dalfampridine—Paraesthesia—Conjugated Estrogens—osteoporosis	0.00167	0.00217	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Zoledronate—osteoporosis	0.00167	0.00216	CcSEcCtD
Dalfampridine—Angioedema—Estradiol—osteoporosis	0.00166	0.00216	CcSEcCtD
Dalfampridine—Rash—Calcitriol—osteoporosis	0.00166	0.00216	CcSEcCtD
Dalfampridine—Dermatitis—Calcitriol—osteoporosis	0.00166	0.00216	CcSEcCtD
Dalfampridine—Dyspnoea—Conjugated Estrogens—osteoporosis	0.00166	0.00215	CcSEcCtD
Dalfampridine—Headache—Calcitriol—osteoporosis	0.00165	0.00215	CcSEcCtD
Dalfampridine—Constipation—Zoledronate—osteoporosis	0.00165	0.00214	CcSEcCtD
Dalfampridine—Nausea—Alendronate—osteoporosis	0.00165	0.00214	CcSEcCtD
Dalfampridine—Hypersensitivity—Risedronate—osteoporosis	0.00164	0.00213	CcSEcCtD
Dalfampridine—Dyspepsia—Conjugated Estrogens—osteoporosis	0.00164	0.00212	CcSEcCtD
Dalfampridine—Asthenia—Ethinyl Estradiol—osteoporosis	0.00164	0.00212	CcSEcCtD
Dalfampridine—Nausea—Raloxifene—osteoporosis	0.00162	0.0021	CcSEcCtD
Dalfampridine—KCNQ2—Axon guidance—CAP1—osteoporosis	0.00161	0.00699	CbGpPWpGaD
Dalfampridine—KCNQ3—Axon guidance—CAP1—osteoporosis	0.00161	0.00699	CbGpPWpGaD
Dalfampridine—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.0016	0.00208	CcSEcCtD
Dalfampridine—Nausea—Ibandronate—osteoporosis	0.0016	0.00208	CcSEcCtD
Dalfampridine—KCNB1—Integration of energy metabolism—ADCY5—osteoporosis	0.0016	0.00696	CbGpPWpGaD
Dalfampridine—CYP2E1—Folate-Alcohol and Cancer Pathway—MTHFR—osteoporosis	0.0016	0.00695	CbGpPWpGaD
Dalfampridine—Asthenia—Risedronate—osteoporosis	0.00159	0.00207	CcSEcCtD
Dalfampridine—Feeling abnormal—Zoledronate—osteoporosis	0.00159	0.00207	CcSEcCtD
Dalfampridine—Constipation—Conjugated Estrogens—osteoporosis	0.00159	0.00206	CcSEcCtD
Dalfampridine—KCNA3—BDNF signaling pathway—SPP1—osteoporosis	0.00158	0.00685	CbGpPWpGaD
Dalfampridine—Nausea—Calcitriol—osteoporosis	0.00157	0.00204	CcSEcCtD
Dalfampridine—Hypersensitivity—Pamidronate—osteoporosis	0.00156	0.00202	CcSEcCtD
Dalfampridine—Chest pain—Estradiol—osteoporosis	0.00155	0.00201	CcSEcCtD
Dalfampridine—Anxiety—Estradiol—osteoporosis	0.00155	0.00201	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.00154	0.002	CcSEcCtD
Dalfampridine—Urticaria—Zoledronate—osteoporosis	0.00153	0.00199	CcSEcCtD
Dalfampridine—Asthenia—Pamidronate—osteoporosis	0.00152	0.00197	CcSEcCtD
Dalfampridine—Dizziness—Ethinyl Estradiol—osteoporosis	0.00151	0.00196	CcSEcCtD
Dalfampridine—Confusional state—Estradiol—osteoporosis	0.0015	0.00195	CcSEcCtD
Dalfampridine—Anaphylactic shock—Estradiol—osteoporosis	0.00149	0.00193	CcSEcCtD
Dalfampridine—Infection—Estradiol—osteoporosis	0.00148	0.00192	CcSEcCtD
Dalfampridine—Urticaria—Conjugated Estrogens—osteoporosis	0.00148	0.00192	CcSEcCtD
Dalfampridine—Dizziness—Risedronate—osteoporosis	0.00147	0.00191	CcSEcCtD
Dalfampridine—Nervous system disorder—Estradiol—osteoporosis	0.00146	0.00189	CcSEcCtD
Dalfampridine—Vomiting—Ethinyl Estradiol—osteoporosis	0.00145	0.00188	CcSEcCtD
Dalfampridine—Skin disorder—Estradiol—osteoporosis	0.00144	0.00188	CcSEcCtD
Dalfampridine—Rash—Ethinyl Estradiol—osteoporosis	0.00144	0.00187	CcSEcCtD
Dalfampridine—Dermatitis—Ethinyl Estradiol—osteoporosis	0.00144	0.00186	CcSEcCtD
Dalfampridine—Headache—Ethinyl Estradiol—osteoporosis	0.00143	0.00185	CcSEcCtD
Dalfampridine—KCNQ1—SIDS Susceptibility Pathways—ESR2—osteoporosis	0.00143	0.0062	CbGpPWpGaD
Dalfampridine—KCNA3—BDNF signaling pathway—IRS2—osteoporosis	0.00143	0.00619	CbGpPWpGaD
Dalfampridine—Hypersensitivity—Zoledronate—osteoporosis	0.00142	0.00185	CcSEcCtD
Dalfampridine—Vomiting—Risedronate—osteoporosis	0.00141	0.00184	CcSEcCtD
Dalfampridine—Rash—Risedronate—osteoporosis	0.0014	0.00182	CcSEcCtD
Dalfampridine—Dermatitis—Risedronate—osteoporosis	0.0014	0.00182	CcSEcCtD
Dalfampridine—Dizziness—Pamidronate—osteoporosis	0.0014	0.00181	CcSEcCtD
Dalfampridine—Headache—Risedronate—osteoporosis	0.00139	0.00181	CcSEcCtD
Dalfampridine—Asthenia—Zoledronate—osteoporosis	0.00138	0.0018	CcSEcCtD
Dalfampridine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.00137	0.00178	CcSEcCtD
Dalfampridine—Nausea—Ethinyl Estradiol—osteoporosis	0.00135	0.00176	CcSEcCtD
Dalfampridine—Insomnia—Estradiol—osteoporosis	0.00134	0.00175	CcSEcCtD
Dalfampridine—Vomiting—Pamidronate—osteoporosis	0.00134	0.00174	CcSEcCtD
Dalfampridine—Paraesthesia—Estradiol—osteoporosis	0.00134	0.00173	CcSEcCtD
Dalfampridine—Asthenia—Conjugated Estrogens—osteoporosis	0.00133	0.00173	CcSEcCtD
Dalfampridine—Rash—Pamidronate—osteoporosis	0.00133	0.00173	CcSEcCtD
Dalfampridine—Dermatitis—Pamidronate—osteoporosis	0.00133	0.00173	CcSEcCtD
Dalfampridine—Dyspnoea—Estradiol—osteoporosis	0.00133	0.00172	CcSEcCtD
Dalfampridine—Headache—Pamidronate—osteoporosis	0.00132	0.00172	CcSEcCtD
Dalfampridine—Nausea—Risedronate—osteoporosis	0.00132	0.00171	CcSEcCtD
Dalfampridine—Dyspepsia—Estradiol—osteoporosis	0.00131	0.0017	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Estradiol—osteoporosis	0.00128	0.00167	CcSEcCtD
Dalfampridine—Dizziness—Zoledronate—osteoporosis	0.00128	0.00166	CcSEcCtD
Dalfampridine—Constipation—Estradiol—osteoporosis	0.00127	0.00165	CcSEcCtD
Dalfampridine—Nausea—Pamidronate—osteoporosis	0.00125	0.00163	CcSEcCtD
Dalfampridine—KCNA3—BDNF signaling pathway—IRS1—osteoporosis	0.00124	0.00541	CbGpPWpGaD
Dalfampridine—Dizziness—Conjugated Estrogens—osteoporosis	0.00123	0.0016	CcSEcCtD
Dalfampridine—Vomiting—Zoledronate—osteoporosis	0.00123	0.00159	CcSEcCtD
Dalfampridine—Feeling abnormal—Estradiol—osteoporosis	0.00123	0.00159	CcSEcCtD
Dalfampridine—Rash—Zoledronate—osteoporosis	0.00122	0.00158	CcSEcCtD
Dalfampridine—Dermatitis—Zoledronate—osteoporosis	0.00122	0.00158	CcSEcCtD
Dalfampridine—Headache—Zoledronate—osteoporosis	0.00121	0.00157	CcSEcCtD
Dalfampridine—KCNB1—Calcium Regulation in the Cardiac Cell—ADCY5—osteoporosis	0.0012	0.00522	CbGpPWpGaD
Dalfampridine—Vomiting—Conjugated Estrogens—osteoporosis	0.00118	0.00153	CcSEcCtD
Dalfampridine—Urticaria—Estradiol—osteoporosis	0.00118	0.00153	CcSEcCtD
Dalfampridine—Rash—Conjugated Estrogens—osteoporosis	0.00117	0.00152	CcSEcCtD
Dalfampridine—Dermatitis—Conjugated Estrogens—osteoporosis	0.00117	0.00152	CcSEcCtD
Dalfampridine—Headache—Conjugated Estrogens—osteoporosis	0.00116	0.00151	CcSEcCtD
Dalfampridine—KCNQ2—Developmental Biology—CAP1—osteoporosis	0.00115	0.00499	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—CAP1—osteoporosis	0.00115	0.00499	CbGpPWpGaD
Dalfampridine—Nausea—Zoledronate—osteoporosis	0.00115	0.00149	CcSEcCtD
Dalfampridine—Nausea—Conjugated Estrogens—osteoporosis	0.0011	0.00143	CcSEcCtD
Dalfampridine—Hypersensitivity—Estradiol—osteoporosis	0.0011	0.00142	CcSEcCtD
Dalfampridine—KCNG3—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNF1—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNH4—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNA2—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNC3—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNH3—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNB2—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNG4—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNG1—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNA7—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNH5—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNS1—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNA10—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNA4—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNC1—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNA6—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNH1—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNS2—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCND1—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNC4—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNA5—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNV1—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNV2—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—KCNH8—Neuronal System—ADCY5—osteoporosis	0.00108	0.00468	CbGpPWpGaD
Dalfampridine—Asthenia—Estradiol—osteoporosis	0.00107	0.00139	CcSEcCtD
Dalfampridine—KCNQ2—Axon guidance—TLN1—osteoporosis	0.00101	0.00438	CbGpPWpGaD
Dalfampridine—KCNQ3—Axon guidance—TLN1—osteoporosis	0.00101	0.00438	CbGpPWpGaD
Dalfampridine—KCNQ2—Axon guidance—ACTG1—osteoporosis	0.000994	0.00432	CbGpPWpGaD
Dalfampridine—KCNQ3—Axon guidance—ACTG1—osteoporosis	0.000994	0.00432	CbGpPWpGaD
Dalfampridine—Dizziness—Estradiol—osteoporosis	0.000983	0.00128	CcSEcCtD
Dalfampridine—KCNA3—Neuronal System—ADCY5—osteoporosis	0.00096	0.00417	CbGpPWpGaD
Dalfampridine—Vomiting—Estradiol—osteoporosis	0.000945	0.00123	CcSEcCtD
Dalfampridine—Rash—Estradiol—osteoporosis	0.000938	0.00122	CcSEcCtD
Dalfampridine—Dermatitis—Estradiol—osteoporosis	0.000937	0.00122	CcSEcCtD
Dalfampridine—Headache—Estradiol—osteoporosis	0.000932	0.00121	CcSEcCtD
Dalfampridine—KCNQ5—Neuronal System—ADCY5—osteoporosis	0.000915	0.00398	CbGpPWpGaD
Dalfampridine—KCNQ4—Neuronal System—ADCY5—osteoporosis	0.000915	0.00398	CbGpPWpGaD
Dalfampridine—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000888	0.00386	CbGpPWpGaD
Dalfampridine—Nausea—Estradiol—osteoporosis	0.000883	0.00115	CcSEcCtD
Dalfampridine—CYP2E1—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000876	0.00381	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—PKM—osteoporosis	0.000784	0.00341	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—PKM—osteoporosis	0.000784	0.00341	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—FDPS—osteoporosis	0.000784	0.00341	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—PKM—osteoporosis	0.000784	0.00341	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—FDPS—osteoporosis	0.000784	0.00341	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—FDPS—osteoporosis	0.000784	0.00341	CbGpPWpGaD
Dalfampridine—KCNG2—Neuronal System—ADCY5—osteoporosis	0.000767	0.00333	CbGpPWpGaD
Dalfampridine—KCNC2—Neuronal System—ADCY5—osteoporosis	0.000767	0.00333	CbGpPWpGaD
Dalfampridine—KCNS3—Neuronal System—ADCY5—osteoporosis	0.000767	0.00333	CbGpPWpGaD
Dalfampridine—KCNH2—SIDS Susceptibility Pathways—GAPDH—osteoporosis	0.000762	0.00331	CbGpPWpGaD
Dalfampridine—KCNQ1—SIDS Susceptibility Pathways—IL6R—osteoporosis	0.00076	0.0033	CbGpPWpGaD
Dalfampridine—KCND3—Neuronal System—ADCY5—osteoporosis	0.000746	0.00324	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—FDPS—osteoporosis	0.000743	0.00323	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—PKM—osteoporosis	0.000743	0.00323	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—PGLS—osteoporosis	0.000743	0.00323	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—PGLS—osteoporosis	0.000743	0.00323	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—GPD2—osteoporosis	0.000743	0.00323	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—GPD2—osteoporosis	0.000743	0.00323	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—PGLS—osteoporosis	0.000743	0.00323	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—GPD2—osteoporosis	0.000743	0.00323	CbGpPWpGaD
Dalfampridine—KCND2—Circadian rythm related genes—LEP—osteoporosis	0.00074	0.00322	CbGpPWpGaD
Dalfampridine—KCNB1—Neuronal System—ADCY5—osteoporosis	0.000727	0.00316	CbGpPWpGaD
Dalfampridine—CYP2E1—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.00072	0.00313	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—TLN1—osteoporosis	0.000719	0.00313	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—TLN1—osteoporosis	0.000719	0.00313	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—ACTG1—osteoporosis	0.000709	0.00308	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—ACTG1—osteoporosis	0.000709	0.00308	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—PGLS—osteoporosis	0.000704	0.00306	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—GPD2—osteoporosis	0.000704	0.00306	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—ATIC—osteoporosis	0.000679	0.00295	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—PNP—osteoporosis	0.000679	0.00295	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—ATIC—osteoporosis	0.000679	0.00295	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—ATIC—osteoporosis	0.000679	0.00295	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—PNP—osteoporosis	0.000679	0.00295	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—PNP—osteoporosis	0.000679	0.00295	CbGpPWpGaD
Dalfampridine—KCND2—Neuronal System—ADCY5—osteoporosis	0.000665	0.00289	CbGpPWpGaD
Dalfampridine—KCNQ1—Neuronal System—ADCY5—osteoporosis	0.000665	0.00289	CbGpPWpGaD
Dalfampridine—KCNH6—Neuronal System—ADCY5—osteoporosis	0.000652	0.00284	CbGpPWpGaD
Dalfampridine—KCNH7—Circadian rythm related genes—LEP—osteoporosis	0.000647	0.00281	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—PNP—osteoporosis	0.000644	0.0028	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—ATIC—osteoporosis	0.000644	0.0028	CbGpPWpGaD
Dalfampridine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000642	0.00279	CbGpPWpGaD
Dalfampridine—KCNH2—Hematopoietic Stem Cell Differentiation—IL1B—osteoporosis	0.000636	0.00276	CbGpPWpGaD
Dalfampridine—KCNA1—Neuronal System—ADCY5—osteoporosis	0.00059	0.00256	CbGpPWpGaD
Dalfampridine—KCNH7—Neuronal System—ADCY5—osteoporosis	0.000581	0.00253	CbGpPWpGaD
Dalfampridine—KCNQ1—SIDS Susceptibility Pathways—IL1B—osteoporosis	0.000578	0.00251	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—OXCT1—osteoporosis	0.000578	0.00251	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—CA2—osteoporosis	0.000578	0.00251	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—CA2—osteoporosis	0.000578	0.00251	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—CA2—osteoporosis	0.000578	0.00251	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—OXCT1—osteoporosis	0.000578	0.00251	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—OXCT1—osteoporosis	0.000578	0.00251	CbGpPWpGaD
Dalfampridine—CYP2E1—Tryptophan metabolism—CYP19A1—osteoporosis	0.000577	0.00251	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—MGLL—osteoporosis	0.000563	0.00245	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—MGLL—osteoporosis	0.000563	0.00245	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—MGLL—osteoporosis	0.000563	0.00245	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—WNT1—osteoporosis	0.000553	0.0024	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—WNT1—osteoporosis	0.000553	0.0024	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—CA2—osteoporosis	0.000548	0.00238	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—OXCT1—osteoporosis	0.000548	0.00238	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—MGLL—osteoporosis	0.000534	0.00232	CbGpPWpGaD
Dalfampridine—KCNH2—SIDS Susceptibility Pathways—ESR2—osteoporosis	0.000528	0.0023	CbGpPWpGaD
Dalfampridine—KCNQ2—Neuronal System—ADCY5—osteoporosis	0.000494	0.00215	CbGpPWpGaD
Dalfampridine—KCNQ3—Neuronal System—ADCY5—osteoporosis	0.000494	0.00215	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—IDH2—osteoporosis	0.000479	0.00208	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—IDH2—osteoporosis	0.000479	0.00208	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—IDH2—osteoporosis	0.000479	0.00208	CbGpPWpGaD
Dalfampridine—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000466	0.00203	CbGpPWpGaD
Dalfampridine—CYP2E1—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.00046	0.002	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—IDH2—osteoporosis	0.000454	0.00197	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—CYP27A1—osteoporosis	0.00045	0.00196	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—CYP27A1—osteoporosis	0.00045	0.00196	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—CYP27A1—osteoporosis	0.00045	0.00196	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—ACP5—osteoporosis	0.000438	0.0019	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—ACP5—osteoporosis	0.000438	0.0019	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—ACP5—osteoporosis	0.000438	0.0019	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—CYP27A1—osteoporosis	0.000427	0.00185	CbGpPWpGaD
Dalfampridine—KCNQ1—SIDS Susceptibility Pathways—TNF—osteoporosis	0.000419	0.00182	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—ACP5—osteoporosis	0.000415	0.0018	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—TPI1—osteoporosis	0.000407	0.00177	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—TPI1—osteoporosis	0.000407	0.00177	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—TPI1—osteoporosis	0.000407	0.00177	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—TPI1—osteoporosis	0.000386	0.00168	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—P4HB—osteoporosis	0.000383	0.00166	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—P4HB—osteoporosis	0.000383	0.00166	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—P4HB—osteoporosis	0.000383	0.00166	CbGpPWpGaD
Dalfampridine—CYP2E1—Biological oxidations—CYP27A1—osteoporosis	0.000382	0.00166	CbGpPWpGaD
Dalfampridine—CYP2E1—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000378	0.00164	CbGpPWpGaD
Dalfampridine—CYP2E1—Metapathway biotransformation—CYP27A1—osteoporosis	0.000377	0.00164	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—GAPDH—osteoporosis	0.000376	0.00163	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—GAPDH—osteoporosis	0.000376	0.00163	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—GAPDH—osteoporosis	0.000376	0.00163	CbGpPWpGaD
Dalfampridine—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—osteoporosis	0.000372	0.00162	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—RAP1A—osteoporosis	0.000366	0.00159	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—RAP1A—osteoporosis	0.000366	0.00159	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—RAP1A—osteoporosis	0.000366	0.00159	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—P4HB—osteoporosis	0.000363	0.00158	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—GAPDH—osteoporosis	0.000356	0.00155	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—RAP1A—osteoporosis	0.000347	0.00151	CbGpPWpGaD
Dalfampridine—KCNQ1—SIDS Susceptibility Pathways—IL6—osteoporosis	0.000338	0.00147	CbGpPWpGaD
Dalfampridine—KCNQ3—Axon guidance—IL6R—osteoporosis	0.000315	0.00137	CbGpPWpGaD
Dalfampridine—KCNQ2—Axon guidance—IL6R—osteoporosis	0.000315	0.00137	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—ENO1—osteoporosis	0.000296	0.00129	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—ENO1—osteoporosis	0.000296	0.00129	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—ENO1—osteoporosis	0.000296	0.00129	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—PSMA5—osteoporosis	0.000291	0.00127	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—PSMA2—osteoporosis	0.000291	0.00127	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—PSMA5—osteoporosis	0.000291	0.00127	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—PSMA5—osteoporosis	0.000291	0.00127	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—PSMA2—osteoporosis	0.000291	0.00127	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—PSMA2—osteoporosis	0.000291	0.00127	CbGpPWpGaD
Dalfampridine—KCNH2—SIDS Susceptibility Pathways—IL6R—osteoporosis	0.000281	0.00122	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—ENO1—osteoporosis	0.00028	0.00122	CbGpPWpGaD
Dalfampridine—CYP2E1—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.00028	0.00122	CbGpPWpGaD
Dalfampridine—KCND2—Circadian rythm related genes—IL6—osteoporosis	0.000276	0.0012	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—PSMA2—osteoporosis	0.000276	0.0012	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—PSMA5—osteoporosis	0.000276	0.0012	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—LEP—osteoporosis	0.000268	0.00116	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—LEP—osteoporosis	0.000268	0.00116	CbGpPWpGaD
Dalfampridine—KCNH2—Neuronal System—ADCY5—osteoporosis	0.000246	0.00107	CbGpPWpGaD
Dalfampridine—KCNH7—Circadian rythm related genes—IL6—osteoporosis	0.000242	0.00105	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—CYP19A1—osteoporosis	0.000236	0.00103	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—CYP19A1—osteoporosis	0.000236	0.00103	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—CYP19A1—osteoporosis	0.000236	0.00103	CbGpPWpGaD
Dalfampridine—CYP2E1—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000227	0.000988	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—IL6R—osteoporosis	0.000225	0.000976	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—IL6R—osteoporosis	0.000225	0.000976	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—CYP19A1—osteoporosis	0.000224	0.000974	CbGpPWpGaD
Dalfampridine—KCNH2—SIDS Susceptibility Pathways—IL1B—osteoporosis	0.000214	0.00093	CbGpPWpGaD
Dalfampridine—CYP2E1—Biological oxidations—CYP19A1—osteoporosis	0.000201	0.000873	CbGpPWpGaD
Dalfampridine—CYP2E1—Metapathway biotransformation—CYP19A1—osteoporosis	0.000198	0.000861	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—ADCY5—osteoporosis	0.000193	0.00084	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—ADCY5—osteoporosis	0.000193	0.00084	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—ADCY5—osteoporosis	0.000193	0.00084	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—GPX1—osteoporosis	0.000193	0.000837	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—GPX1—osteoporosis	0.000193	0.000837	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—GPX1—osteoporosis	0.000193	0.000837	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—ADCY5—osteoporosis	0.000183	0.000796	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—GPX1—osteoporosis	0.000183	0.000793	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—MTHFR—osteoporosis	0.000178	0.000772	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—MTHFR—osteoporosis	0.000178	0.000772	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—MTHFR—osteoporosis	0.000178	0.000772	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—MTHFR—osteoporosis	0.000168	0.000732	CbGpPWpGaD
Dalfampridine—KCNH2—SIDS Susceptibility Pathways—TNF—osteoporosis	0.000155	0.000675	CbGpPWpGaD
Dalfampridine—KCNC2—Metabolism—POMC—osteoporosis	0.000142	0.000618	CbGpPWpGaD
Dalfampridine—KCNG2—Metabolism—POMC—osteoporosis	0.000142	0.000618	CbGpPWpGaD
Dalfampridine—KCNS3—Metabolism—POMC—osteoporosis	0.000142	0.000618	CbGpPWpGaD
Dalfampridine—KCNQ2—Axon guidance—IL6—osteoporosis	0.00014	0.000609	CbGpPWpGaD
Dalfampridine—KCNQ3—Axon guidance—IL6—osteoporosis	0.00014	0.000609	CbGpPWpGaD
Dalfampridine—KCNB1—Metabolism—POMC—osteoporosis	0.000135	0.000586	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—TGFB1—osteoporosis	0.000133	0.000577	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—TGFB1—osteoporosis	0.000133	0.000577	CbGpPWpGaD
Dalfampridine—KCNH2—SIDS Susceptibility Pathways—IL6—osteoporosis	0.000125	0.000545	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—TNF—osteoporosis	0.000124	0.000539	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—TNF—osteoporosis	0.000124	0.000539	CbGpPWpGaD
Dalfampridine—CYP2E1—Biological oxidations—POMC—osteoporosis	0.000121	0.000525	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—FDPS—osteoporosis	0.000114	0.000495	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—PKM—osteoporosis	0.000114	0.000495	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—PGLS—osteoporosis	0.000108	0.000469	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—GPD2—osteoporosis	0.000108	0.000469	CbGpPWpGaD
Dalfampridine—KCNQ3—Developmental Biology—IL6—osteoporosis	0.0001	0.000435	CbGpPWpGaD
Dalfampridine—KCNQ2—Developmental Biology—IL6—osteoporosis	0.0001	0.000435	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—PNP—osteoporosis	9.87e-05	0.000429	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—ATIC—osteoporosis	9.87e-05	0.000429	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—CA2—osteoporosis	8.39e-05	0.000365	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—OXCT1—osteoporosis	8.39e-05	0.000365	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—MGLL—osteoporosis	8.18e-05	0.000356	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—IDH2—osteoporosis	6.96e-05	0.000302	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—CYP27A1—osteoporosis	6.54e-05	0.000284	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—ACP5—osteoporosis	6.36e-05	0.000277	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—TPI1—osteoporosis	5.91e-05	0.000257	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—P4HB—osteoporosis	5.56e-05	0.000242	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—GAPDH—osteoporosis	5.46e-05	0.000237	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—RAP1A—osteoporosis	5.32e-05	0.000231	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—ENO1—osteoporosis	4.3e-05	0.000187	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—PSMA2—osteoporosis	4.23e-05	0.000184	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—PSMA5—osteoporosis	4.23e-05	0.000184	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—CYP19A1—osteoporosis	3.44e-05	0.000149	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—ADCY5—osteoporosis	2.81e-05	0.000122	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—GPX1—osteoporosis	2.8e-05	0.000122	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—MTHFR—osteoporosis	2.58e-05	0.000112	CbGpPWpGaD
Dalfampridine—CYP2E1—Metabolism—POMC—osteoporosis	2.06e-05	8.97e-05	CbGpPWpGaD
